Tumors arising in the gallbladder, bile ducts, and the small intestine are collectively referred to as biliary tract cancers. These cancers are rare—affecting approximately 12,350 individuals in 2024—but they are typically diagnosed at advanced stages when surgery, which can improve prognosis, is no longer an option. Angela Lamarca, MD, PhD Systemic therapies, therefore, are the… Continue reading Making Biliary Tract Cancer Treatment More Precise
Tag: Breast Cancer
Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR
Human epidermal growth factor receptor 2 (HER2) is a critical therapeutic target for HER2-positive or HER2-dependent cancers. While several HER2 kinase inhibitors have been identified, achieving high selectivity for HER2 over EGFR remains a significant challenge. In this study, we aimed to develop HER2-selective inhibitors with enhanced cellular activity. To improve the limited cellular activity… Continue reading Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2 -Positive Breast Cancer
This 10-year follow-up analysis of the ShortHER randomized clinical trial evaluates the association of tumor-infiltrating lymphocytes with distant disease-free and overall survival among patients with ERBB2 (formerly HER2)–positive early breast cancer.
Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer
This cohort study examines interruption and resumption of endocrine therapy among women with breast cancer who became pregnant.
Innovative dual-target drug may lead to new investigational approach for breast cancer patients
Researchers discover new insights into how dual-target drug may supercharge cancer-fighting immune cells.
New dual-target therapy offers hope for better breast cancer treatment
Researchers, led by the University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, have discovered new insights into possible future treatments for breast cancer. A new dual-target drug that has been shown to supercharge cancer-fighting immune… Continue reading New dual-target therapy offers hope for better breast cancer treatment
Estimating cancer incidence attributable to physical inactivity in the United States
Abstract Background Previous estimates of the number of cancers attributable to physical inactivity in the United States have typically focused on only three malignancies (colon, endometrial, and postmenopausal breast cancer). Contemporary epidemiologic evidence suggests that physical inactivity could contribute to up to 15 types of cancer, and a dose–response effect has been demonstrated for 13… Continue reading Estimating cancer incidence attributable to physical inactivity in the United States
Estimating cancer incidence attributable to physical inactivity in the United States
Abstract Background Previous estimates of the number of cancers attributable to physical inactivity in the United States have typically focused on only three malignancies (colon, endometrial, and postmenopausal breast cancer). Contemporary epidemiologic evidence suggests that physical inactivity could contribute to up to 15 types of cancer, and a dose–response effect has been demonstrated for 13… Continue reading Estimating cancer incidence attributable to physical inactivity in the United States
Breast cancer treatment advances with light-activated ‘smart bomb’
Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with minimal side effects. In mouse tests, the new therapy completely eradicated metastatic breast cancer tumors.
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
TROPION-Breast01 (NCT05104866) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with the TROP2-directed ADC Dato-DXd vs investigator’s choice of CT (ICC) in patients (pts) with previously treated, inoperable/metastatic HR+/HER2– BC (HR 0.63 [95% CI 0.52–0.76]; p<0.0001). We report the final OS analysis and updated safety.